
Phathom Pharmaceuticals (PHAT) Stock Forecast & Price Target
Phathom Pharmaceuticals (PHAT) Analyst Ratings
Bulls say
Phathom Pharmaceuticals Inc. is poised for continued commercial growth, driven by expanding its prescriber base, particularly among primary care providers treating the non-erosive gastroesophageal reflux disease (NERD) segment. The company reported significant increases in filled prescriptions for its product VOQUEZNA, reaching over 300,000 since launch and demonstrating a 110% growth from previous figures. Additionally, the 4Q24 revenue of $29.7 million exceeded expectations, bolstering management's confidence in positive outcomes from upcoming regulatory decisions and overall market expansion.
Bears say
Phathom Pharmaceuticals has faced substantial stock pressure primarily due to uncertainties regarding the patent exclusivity of its product, Voquezna, which is likely to persist and weigh on the stock’s performance. Financially, the company reported a decrease in cash reserves, ending the fourth quarter of 2024 with $297 million, down from $335 million in the previous quarter, indicating potential cash flow challenges. Additionally, anticipated softer revenues for the first quarter of 2025 due to seasonal headwinds and inventory fluctuations further contribute to a negative financial outlook, compounded by risks related to product performance and securing necessary funding for operations.
This aggregate rating is based on analysts' research of Phathom Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Phathom Pharmaceuticals (PHAT) Analyst Forecast & Price Prediction
Start investing in Phathom Pharmaceuticals (PHAT)
Order type
Buy in
Order amount
Est. shares
0 shares